

Biotech Business Week

April 7, 2003

TISSUE PROCESSING: LifeTek, Inc., and DCI license technology to terminally sterilize tissues

BODY: Services - have finalized agreements with Clearant, Inc., to license the company's patented pathogen inactivation process in order to begin providing hospitals and patients with safer, sterile tissue allografts.

Prior to the introduction of the Clearant process, tissues were aseptically processed because there was no technology available that allowed tissue banks to significantly eliminate the risk of pathogen transmissions and terminally sterilize tissues without damaging the function of the allograft.

The Clearant process substantially reduces all types of pathogens, including bacteria and viruses, which may be present in human tissue without compromising the quality of the tissue, according to Clearant.

In addition, the Clearant process, based on gamma irradiation, is designed to be used for allograft tissue in the final container, thereby allowing the final product to be "terminally sterile" for use in the operating room.

This article was prepared by Biotech Business Week editors from staff and other reports.

<http://www.NewsRx.net>